Hepcludex is now the first and only approved treatment for HDV patients in the US, marking a significant milestone for the HDV market.

Hansa Biopharma’s Idefrix (imlifidase) has seen a 90% one-year survival from GvHD in patients following a kidney transplant.

Eli Lilly and Company has reported positive interim results from the ongoing Phase Ib Heart-2 clinical trial of VERVE-102.

Bial has completed the treatment in its Phase IIb ACTIVATE clinical trial evaluating BIA 28-6156 in PD patients with a pathogenic mutation in GBA-PD.

Lilly's retatrutide may have the best weight loss efficacy so far, but analysts are concerned around its tolerability compared with tirzepatide.

Lilly’s weight loss pill gained approval in April 2026, around three months after Novo Nordisk gained the same accolade for oral Wegovy.

While Vincentage's study will only support approval of the oral GLP-1RA in China, the drug is in a Phase II trial in the US.

As China continues to inch ahead of competition in terms of trial initiations, immunology and metabolic disease trials attract sponsor eyes.

As the first half of 2026 draws to a close, experts at Arena International’s OCT East Coast reflect on the key trends shaping the sector.

Merck KGaA has dosed the first patient in its Phase III PROCEADE-CRC-03 trial, assessing the investigational anti-CEACAM5 ADC precemtabart tocentecan for mCRC.

Biogen and Denali Therapeutics have reported data from the Phase IIb LUMA study evaluating BIIB122 for early-stage Parkinson’s disease.

Pfizer has reported positive results from its Phase II trial evaluating the 25-valent pneumococcal conjugate vaccine candidate, PF-07872412, in infants.